Pritelivir, a nonnucleoside helicase-primase inhibitor, for the treatment of herpes simplex virus (HSV) infections in Phase 3 clinical development. (IDWeek 2025) - Sep 3, 2025 - Abstract #51; Pres time: Oct 20, 2025; 08:48 AM - 09:00 AM; Location: B302-B304; No abstract available
Clinical • P3 data • Herpes Simplex • Infectious Disease
|
|
Alexander Birkmann, PhD (he/him/his)
|